Biotech company Debut expands into fragrance category following Series B funding increase

Biotech company Debut expands into fragrance category following Series B funding increase

Earlier this year, CosmeticsDesign reported​ that biotech company Debut secured $34 million in Series B funding from vested partners, including L’Oreal’s venture capital fund BOLD. Earlier this month, the company announced that its latest Series B funding round, led by L’Oreal, had reached $40 million. 

The company, which has previously focused on providing manufacturers of cosmetic and personal care products with novel ingredients utilizing its proprietary cell-free and advanced fermentation processes, will use some of the increased funding to expand into the fragrance category. To learn more about how Debut is pivoting into novel fragrance molecule development, how the company is working better to meet the needs of manufacturing companies in this sector, and the innovations made so far in the fragrance space, CosmeticsDesign-USA (CDU) interviewed Joshua Britton, the Founder and CEO of Debut for his insights. 

CDU: How is Debut leveraging its proprietary biomanufacturing platform to develop bio-identical and novel fragrance molecules?

Joshua Britton (JB): The fragrance industry is at a critical juncture: on the one hand, the consumer drive for natural ingredients is unabating, and on the other hand, the pressure on the planet’s dwindling natural resources is unsustainable. Add to that the large petroleum-based palette of synthetic fragrance ingredients, much of which is under the threat of regulation, and you have a perfect fragrance storm in the making. Advanced biomanufacturing is the only solution that can scale at the level of consumption of the fragrance industry, producing natural ingredients at peak purity, quality, and safety and devoid of allergens. 

Source link

About The Author

Scroll to Top